From: Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
 | Rheumatoid arthritis | Axial spondyloarthritis | Psoriatic arthritis | Healthy control | p value |
---|---|---|---|---|---|
n | 969 | 451 | 237 | 72 | Â |
Gender = male§ | 250 (25.8) | 268 (59.4) | 136 (57.4) | 13 (18.1) | < 0.01 |
Age, year | 57.6 (13.2) | 44.0 (12.3) | 51.5 (12.2) | 56.5 (8.3) | < 0.01 |
Disease duration, year | 10.9 (10.1) | 9.9 (9.8) | 7.9 (8.4) | – | < 0.01 |
BMI kg/m2 | 26.2 (5.4) | 26.0 (4.9) | 27.5 (5.4) | 24.1 (3.4) | < 0.01 |
Smoker§ | 435/758 (57.4) | 146/264 (55.3) | 101/168 (60.1) | 34/72 (47.2) | 0.37 |
Calprotectin μg/ml* | 2.6 [1.7, 4.3] | 2.4 [1.6, 3.9] | 2.2 [1.4, 3.4] | 1.2 [0.8, 2.0] | < 0.01 |
CRP mg/l* | 3.0 [1.0, 7.9] | 3.0 [1.0, 8.0] | 3.0 [1.0, 7.9] | – | 0.39 |
ESR mm/h* | 12.0 [6.0, 22.0] | 8.0 [4.0, 17.0] | 8.0 [3.0, 14.0] | – | 0.62 |
Swollen joint count* | 1.0 [0.0, 3.0] | 0.0 [0.0, 0.0] | 0.0 [0.0, 2.0] | – | < 0.01 |
Disease activity score1 | 2.8 [2.0, 3.9] | 2.3 [1.5, 3.2] | 12 [5.1, 24.0] |  | – |
Patients on GCS§ | 277 (28.6) | 3 (0.7) | 19 (8.0) | – | < 0.01 |
Patients on cDMARDS§ | 645 (66.6) | 75 (16.6) | 142 (59.9) | – | < 0.01 |
Patients on bDMARDS§ | 557 (57.5) | 184 (40.8) | 108 (45.6) | – | < 0.01 |
TNFi§ | 205 (21.2) | 180 (39.9) | 100 (42.2) |  | < 0.01 |
Tocilizumab§ | 92 (9.5) | 3 (0.7) | 3 (1.3) |  | < 0.01 |
Rituximab§ | 172 (17.8) | 0 (0.0) | 1 (0.4) |  | < 0.01 |